Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles


Weir-Torn Jiaang, Ph.D.

Investigator
Institute of Biotechnology and Pharmaceutical Research
wtjiaang@nhri.org.tw

EDUCATION

Ph.D., Organic Chemistry, National Taiwan University, Taipei, Taiwan (1996)
M.S., Organic Chemistry, Tamkang University, Taipei, Taiwan (1991)
B.S., Chemistry, Tamkang University, Taipei, Taiwan (1989)

PROFESSIONAL EXPERIENCES

Investigator, Institute of Biotechnology and Pharmaceutical Research, NHRI (2011-present)
Associate Investigator, Division of Biotechnology and Pharmaceutical Research, NHRI (2006-2011)
Assistant Investigator, Division of Biotechnology and Pharmaceutical Research, NHRI (2002-2006)
Investigator, Union Chemical Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan (2000-2002)
Postdoctoral Fellow, Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan (1996-2000)

RESEARCH INTERESTS

Dr. Jiaang's research interests include organic synthesis, radical chemistry, carbohydrate chemistry, peptide synthesis, and photopolymer chemistry for Integrated Circuit (IC) and Flat Panel Display (FPD). A main current focus of his research is the discovery of DPP-IV inhibitors for the treatment of type II diabetes.

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

At NHRI, Dr. Jiaang's first project focused on the discovery of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type II diabetes. In this project, Dr. Jiaang has successfully identified a potent and selective DPP-IV inhibitor, DBPR108, currently in clinical development. Currently, Dr. Jiaang is developing new anti-cancer drugs, such as FLT3 inhibitors for the treatment of acute myeloid leukemia. Dr. Jiaang has 38 publications related to his research areas in organic, medicinal and polymer chemistry in SCI journals and has awarded five US patents.

SELECTED PUBLICATIONS

1.Ting-Yueh Tsai, Tsu Hsu, Chiung-Tong Chen, Jai-Hong Cheng, Mei-Chun Chiou, Chih-Hsiang Huang, Ya-Ju Tseng, Teng-Kuang Yeh, Chung-Yu Huang, Kai-Chia Yeh, Yu-Wen Huang, Ssu-Hui Wu, Min-Hsien Wang, Xin Chen, Yu-Sheng Chao and Weir-Torn Jiaang.* Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 1908-1912.
2.Ting-Yueh Tsai, Tsu Hsu, Chiung-Tong Chen, Jai-Hong Cheng, Teng-Kuang Yeh, Xin Chen, Chung-Yu Huang, Chung-Nien Chang, Kai-Chia Yeh, Su-Huei Hsieh, Chia-Hui Chien, Yi-Wei Chang, Chih-Hsiang Huang, Yu-Wen Huang, Chen-Lung Huang, Ssu-Hui Wu, Min-Hsien Wang, Cheng-Tai Lu, Yu-Sheng Chao and Weir-Torn Jiaang.* Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. 2009, 17, 2388-2399.
3.Tsu Hsu, Chiung-Tong Chen, Ting-Yueh Tsai, Jai-Hong Cheng, Su-Ying Wu, Chung-Nien Chang, Chia-Hui Chien, Kai-Chia Yeh, Yu-Wen Huang, Chen-Lung Huang, Chung-Yu Huang, Ssu-Hui Wu, Yi-Kun Chiang, Min-Hsien Wang, Yu-Sheng Chao, Xin Chen and Weir-Torn Jiaang* (1,3-Diphenyl-1H-pyrazol-4-yl)-methylamine analogues as inhibitors of dipeptidyl peptidases. J. Chin. Chem. Soc. 2009, 56, 1048-1055.
4.Teng-Kuang Yeh, Ting-Yueh Tsai, Tsu Hsu, Jai-Hong Cheng, Xin Chen, Jen-Shin Song, Horng-Shing Shy, Mei-Chun Chiou, Chia-Hui Chien, Ya-Ju Tseng, Chung-Yu Huang, Kai-Chia Yeh, Yu-Lin Huang, Chih-Hsiang Huang, Yu-Wen Huang, Min-Hsien Wang, Hung-Kuan Tang, Yu-Sheng Chao, Chiung-Tong Chen* and Weir-Torn Jiaang.* (2S,4S)-1-[2-(1,1-Dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyr rolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. 2010, 20, 3596-3600.
5.Ting-Yueh Tsai, Teng-Kuang Yeh, Xin Chen, Tsu Hsu, Yu-Chen Jao, Chih-Hsiang Huang, Jen-Shin Song, Yu-Chen Huang, Chia-Hui Chien, Jing-Huai Chiu, Hung-Kuan Tang, Yu-Sheng Chao and Weir-Torn Jiaang.* Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein. J. Med. Chem. 2010, 53, 6572-6582.
6.Tsu Hsu, Ting-Yueh Tsai, Ya-Ju Tseng, Mei-Chun Chiou, Cheng-Tai Lu, Yu-Sheng Chao and Weir-Torn Jiaang.*"Synthesis of 3,3-Dimethylglutamic Acid Derivatives as DPP-IV Inhibitors and Evaluation of Their Chemical Stability. J. Chin. Chem. Soc., 2011, 58, 1-10.
7.Shu-Jen Chen, Weir-Torn Jiaang.* Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein. Curr. Top. Med. Chem. 2011, 11, 1447-1463.
8.Wen-Hsing Lin, Shu-Yi Hsieh, Shih-Chieh Yen,1 Chiung-Tong Chen, Teng-Kuang Yeh, Tsu Hsu, Cheng-Tai Lu, Ching-Ping Chen, Chun-Wha Chen, Ling-Hui Chou, Yu-Lin Huang, An-Huei Cheng, Yun-I Chang, Ya-Ju Tseng, Kuei-Rong Yen, Yu-Sheng Chao, John T.-A. Hsu,* Weir-Torn Jiaang.* Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). Bioorg. Med. Chem. 2011, 19, 4173-4182.
9.Wen-Hsing Lin, Weir-Torn Jiaang, Kuei-Rong Yen, Tsu Hsu, Ching-Ping Chen, Kai-Yen Chang, Chun-Wha Chen, Chung-Yu Chang, Yu-Sheng Chao, Chiung-Tong Chen,* John T.-A. Hsu.* BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. Br. J. Cancer. 2012, 106, 475-481.
10.John T.-A. Hsu, Teng-Kuang Yeh, Shih-Chieh Yen, Chiung-Tong Chen, Shu-Yi Hsieh, Tsu Hsu, Cheng-Tai Lu, Chun-Hwa Chen, Ling-Hui Chou, Ching-Hui Chiu, Yun-I Chang, Ya-Ju Tseng, Kuei-Rong Yen, Yu-Sheng Chao, Wen-Hsing Lin,* Weir-Torn Jiaang.* 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). Bioorg. Med. Chem. Lett. 2012, 22, 4654-4659.
11.Wen-Hsing Lin, John T.-A. Hsu†, Shu-Yi Hsieh†, Chiung-Tong Chen, Jen-Shin Song, Shih-Chieh Yen, Tsu Hsu, Cheng-Tai Lu, Chun-Hwa Chen, Ling-Hui Chou, Yung-Ning Yang, Ching-Hui Chiu, Ching-Ping Chen, Ya-Ju Tseng, Kuei-Jung Yen, Ching-Fang Yeh, Yu-Sheng Chao, Teng-Kuang Yeh*, Weir-Torn Jiaang.* Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). Bioorg Med Chem. 2013, 21, 2856-67.

PATENT

1.US 7,687,504 B2, TWI299039 and PCT (AU, Korea, Macao, Canada and CN, allowance)"Pyrrolidine Compounds".
2.US 7,425,633 B2"Pyrrolidine Compound"
3.US 8,022,096 B2"Pyrrolidine Derivatives".